KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $81.2 million.

  • Ionis Pharmaceuticals' Cash from Financing Activities fell 8362.7% to $81.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year decrease of 9279.66%. This contributed to the annual value of $478.1 million for FY2024, which is 2577.68% down from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Cash from Financing Activities stood at $81.2 million, which was down 8362.7% from $1.2 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $496.0 million during Q3 2024, with a 5-year trough of -$62.5 million in Q4 2021.
  • For the 5-year period, Ionis Pharmaceuticals' Cash from Financing Activities averaged around $73.5 million, with its median value being $1.8 million (2022).
  • Over the last 5 years, Ionis Pharmaceuticals' Cash from Financing Activities had its largest YoY gain of 1171382.72% in 2023, and its largest YoY loss of 185937.84% in 2023.
  • Ionis Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$62.5 million in 2021, then rose by 18.36% to -$51.0 million in 2022, then skyrocketed by 179.82% to $40.7 million in 2023, then tumbled by 208.33% to -$44.1 million in 2024, then skyrocketed by 284.1% to $81.2 million in 2025.
  • Its Cash from Financing Activities stands at $81.2 million for Q3 2025, versus $1.2 million for Q2 2025 and $2.2 million for Q1 2025.